|Videos|May 27, 2016
An Increased Emphasis on Individual Risk Factors and Goals
Advertisement
Episodes in this series
Zachary T. Bloomgarden, MD, MACE: We talked about lipid-lowering treatment and the notion that the idea of goals has recently been questioned. So, I certainly think that goals are a good way of treating cholesterol, but there are some controversies about that.
We use goals in treating all medical conditions. We use goals in treating blood pressure—we have to decide what the right blood pressure goal is for a given individual and then aim for that. We use goals in treating diabetes—we have to decide what the right A1C goal or fasting plasma glucose goal is for a given individual, and then stay with that. I’m completely in favor of the use of goals, as long as we do it in a rational fashion and apply it correctly.
Advertisement
Related to this article
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care
3
GLP-1s Have Protective Benefit Against DME, Glaucoma Surgery
4
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
5